Vaikom Subramanian Mahadevan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vaikom Subramanian Mahadevan has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
Harsh Agrawal
Department of Medicine Division of Cardiology, University of California-San Francisco, San Francisco, California, USA
5 shared publicationsBernard Clarke
Manchester Royal Infirmary, Central Manchester University Hospitals NHS Trust, Manchester, United Kingdom
4 shared publicationsDavid Blusztein
Division of Cardiology, Department of Medicine, Columbia University Medical Center , 622 West 168th Street, New York, NY 10032 , USA
4 shared publicationsTahir Hamid
Manchester Royal Infirmary, University of Central Manchester NHS foundation Trust , Manchester , UK
4 shared publications- Bernard Clarke
Manchester Heart Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
3 shared publications Dennis Kim
Emory University, Atlanta, GA (D. Kim, V.B.).
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8319
Calcium-Modification Techniques in Calcified Coronary Artery Disease: A Systematic Review of Comparative Evidence on Procedural Success, Complications and Clinical Outcomes
Background/Objectives: Severe coronary calcification complicates percutaneous coronary intervention (PCI), and several calcium-modification technologies are available, but direct randomized comparisons are limited. We reviewed the comparative evidence on procedural success, complications and clinical outcomes. Methods: Comparative studies of coronary calcium-modification techniques during PCI that reported procedural, safety or clinical outcomes were eligible. PubMed and ClinicalTrials.gov were searched in May 2025 for records published from 1 April 2015 to 1 April 2025 (PROSPERO CRD420251077471; no external funding). We included 32 publications: eight randomized trials (10 publications) and 22 observational or descriptive studies. Evidence was organized in tiers and synthesized descriptively, without pooling, because definitions were heterogeneous and event rates were low. Risk of bias in randomized trials was assessed with RoB 2 where full texts were accessible. Results: Procedural success was generally high (usually 85–100%) and major complications were uncommon, but success definitions differed, and reported dissection (0% to over 80%) and slow-flow (0% to 31.6%) rates varied widely. Most comparative data were observational. In randomized comparisons, no device consistently outperformed another for procedural success, stent expansion or minimal stent area. Clinical outcome comparisons were limited by heterogeneous endpoints and low event rates. Risk of bias was rated from full texts for five out of the eight randomized trials, none at low risk overall; ratings for the others were provisional or not possible. Conclusions: The evidence is largely observational and of low certainty, and is insufficient to establish clinically meaningful differences among most technologies. Device selection should be lesion-specific and imaging-informed, and adequately powered head-to-head trials with standardized endpoints are needed.
- 26 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8319
Open AccessCalcium-Modification Techniques in Calcified Coronary Artery Disease: A Systematic Review of Comparative Evidence on Procedural Success, Complications and Clinical Outcomes
Background/Objectives: Severe coronary calcification complicates percutaneous coronary intervention (PCI), and several calcium-modification technologies are available, but direct randomized comparisons are limited. We reviewed the comparative evidence on procedural success, complications and clinical outcomes. Methods: Comparative studies of coronary calcium-modification techniques during PCI that reported procedural, safety or clinical outcomes were eligible. PubMed and ClinicalTrials.gov were searched in May 2025 for records published from 1 April 2015 to 1 April 2025 (PROSPERO CRD420251077471; no external funding). We included 32 publications: eight randomized trials (10 publications) and 22 observational or descriptive studies. Evidence was organized in tiers and synthesized descriptively, without pooling, because definitions were heterogeneous and event rates were low. Risk of bias in randomized trials was assessed with RoB 2 where full texts were accessible. Results: Procedural success was generally high (usually 85–100%) and major complications were uncommon, but success definitions differed, and reported dissection (0% to over 80%) and slow-flow (0% to 31.6%) rates varied widely. Most comparative data were observational. In randomized comparisons, no device consistently outperformed another for procedural success, stent expansion or minimal stent area. Clinical outcome comparisons were limited by heterogeneous endpoints and low event rates. Risk of bias was rated from full texts for five out of the eight randomized trials, none at low risk overall; ratings for the others were provisional or not possible. Conclusions: The evidence is largely observational and of low certainty, and is insufficient to establish clinically meaningful differences among most technologies. Device selection should be lesion-specific and imaging-informed, and adequately powered head-to-head trials with standardized endpoints are needed.
- Open Access
- 20 July 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (6) , 1261-1265
Distribution-based thresholds for clinically important differences in patient-reported outcomes for adults with congenital heart disease
- 20 July 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (6) , 1261-1265
Open AccessDistribution-based thresholds for clinically important differences in patient-reported outcomes for adults with congenital heart disease
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016361
Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial
BACKGROUND: The COMPASSION S3 trial (Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional Transcatheter Heart Valve) was designed to evaluate the safety and effectiveness of the SAPIEN 3 transcatheter heart valve (THV) for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position. Here, 5-year clinical and hemodynamic outcomes for patients in the main cohort and the continued access protocol are reported. METHODS: The COMPASSION S3 trial was a single-arm, multicenter study enrolling patients with either moderate-to-severe pulmonic regurgitation, a mean RVOT gradient ≥35 mm Hg, or both. The primary end point was THV dysfunction at 1 year, a nonhierarchical composite of RVOT reintervention, ≥moderate total pulmonic regurgitation, and mean RVOT gradient >40 mm Hg. Clinical and echocardiographic outcomes were assessed at baseline, discharge, 30 days, 6 months, 1 year, and then annually to 5 years. RESULTS: Between 2016 and 2020, 69 patients were enrolled and successfully implanted with the SAPIEN 3 THV. The mean patient age was 32.1 years, and most patients (70.8%) had a conduit as the most recent prior intervention. At 5 years, the rate of THV dysfunction was 12.0%: 3 patients required reintervention, 2 patients had ≥moderate pulmonic regurgitation, and 1 patient had a mean gradient >40 mm Hg. There were 3 cases of device-related endocarditis (4.4%). One death occurred on postoperative day 560 due to cardiogenic shock. No cases of tricuspid valve injury, stent fractures, or valve malposition were reported. Post-transcatheter pulmonic valve replacement, mean gradients were low and stable through 5-year follow-up. Through 5 years, >95% of patients had ≤mild total pulmonic regurgitation, and 97.9% of patients had none/trace paravalvular regurgitation. CONCLUSIONS: Five-year results from the COMPASSION S3 trial demonstrate that the SAPIEN 3 THV provides durable RVOT relief with low rates of reintervention or endocarditis, supporting the device as a safe and versatile option for transcatheter pulmonic valve replacement across diverse anatomies and clinical scenarios. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02744677.
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016361
Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial
BACKGROUND: The COMPASSION S3 trial (Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional Transcatheter Heart Valve) was designed to evaluate the safety and effectiveness of the SAPIEN 3 transcatheter heart valve (THV) for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position. Here, 5-year clinical and hemodynamic outcomes for patients in the main cohort and the continued access protocol are reported. METHODS: The COMPASSION S3 trial was a single-arm, multicenter study enrolling patients with either moderate-to-severe pulmonic regurgitation, a mean RVOT gradient ≥35 mm Hg, or both. The primary end point was THV dysfunction at 1 year, a nonhierarchical composite of RVOT reintervention, ≥moderate total pulmonic regurgitation, and mean RVOT gradient >40 mm Hg. Clinical and echocardiographic outcomes were assessed at baseline, discharge, 30 days, 6 months, 1 year, and then annually to 5 years. RESULTS: Between 2016 and 2020, 69 patients were enrolled and successfully implanted with the SAPIEN 3 THV. The mean patient age was 32.1 years, and most patients (70.8%) had a conduit as the most recent prior intervention. At 5 years, the rate of THV dysfunction was 12.0%: 3 patients required reintervention, 2 patients had ≥moderate pulmonic regurgitation, and 1 patient had a mean gradient >40 mm Hg. There were 3 cases of device-related endocarditis (4.4%). One death occurred on postoperative day 560 due to cardiogenic shock. No cases of tricuspid valve injury, stent fractures, or valve malposition were reported. Post-transcatheter pulmonic valve replacement, mean gradients were low and stable through 5-year follow-up. Through 5 years, >95% of patients had ≤mild total pulmonic regurgitation, and 97.9% of patients had none/trace paravalvular regurgitation. CONCLUSIONS: Five-year results from the COMPASSION S3 trial demonstrate that the SAPIEN 3 THV provides durable RVOT relief with low rates of reintervention or endocarditis, supporting the device as a safe and versatile option for transcatheter pulmonic valve replacement across diverse anatomies and clinical scenarios. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02744677.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015873
Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials
BACKGROUND: The Alterra Adaptive Prestent provides a landing zone for implantation of the 29 mm SAPIEN 3 transcatheter heart valve (THV) in patients with a dysfunctional right ventricular outflow tract (RVOT) to treat pulmonary regurgitation (PR). Here, we report 3-year outcomes from a pooled analysis of patients who underwent Alterra/SAPIEN 3 THV implantation enrolled in the ALTERRA pivotal trial, Continued Access Protocol, and Pulmonic Delivery System Registry. METHODS: This multicenter, prospective trial enrolled patients with moderate or greater PR and RVOT/pulmonary valve anatomy suitable for implantation. The nonhierarchical composite end point of THV dysfunction was examined at 6 months: RVOT/pulmonary valve reintervention, moderate or greater PR, and mean RVOT/pulmonary valve gradient ≥35 mm Hg. Individual components of the composite, as well as additional clinical and echocardiographic outcomes were examined up to 3 years. RESULTS: The Alterra/SAPIEN 3 THV system was implanted in 118 patients at 14 sites. At 6 months, THV dysfunction was 3.5% (4/113). At 3 years, 97.3% of patients in the valve implant population had freedom from reintervention, 100% of patients had a mean RVOT/pulmonary valve gradients <35 mm Hg, and 93.3% of patients had mild or lesser total PR. The Kaplan-Meier estimate of all-cause mortality was 3.5% at 3 years. There were no cases of coronary artery compression, hemopericardium, or endocarditis. CONCLUSIONS: This analysis reports the longest follow-up in the largest cohort of patients from the ALTERRA trials. The Alterra Adaptive Prestent with the SAPIEN 3 THV system has shown excellent procedural outcomes and is effective in reducing PR at 3-year follow-up. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03130777.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015873
Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials
BACKGROUND: The Alterra Adaptive Prestent provides a landing zone for implantation of the 29 mm SAPIEN 3 transcatheter heart valve (THV) in patients with a dysfunctional right ventricular outflow tract (RVOT) to treat pulmonary regurgitation (PR). Here, we report 3-year outcomes from a pooled analysis of patients who underwent Alterra/SAPIEN 3 THV implantation enrolled in the ALTERRA pivotal trial, Continued Access Protocol, and Pulmonic Delivery System Registry. METHODS: This multicenter, prospective trial enrolled patients with moderate or greater PR and RVOT/pulmonary valve anatomy suitable for implantation. The nonhierarchical composite end point of THV dysfunction was examined at 6 months: RVOT/pulmonary valve reintervention, moderate or greater PR, and mean RVOT/pulmonary valve gradient ≥35 mm Hg. Individual components of the composite, as well as additional clinical and echocardiographic outcomes were examined up to 3 years. RESULTS: The Alterra/SAPIEN 3 THV system was implanted in 118 patients at 14 sites. At 6 months, THV dysfunction was 3.5% (4/113). At 3 years, 97.3% of patients in the valve implant population had freedom from reintervention, 100% of patients had a mean RVOT/pulmonary valve gradients <35 mm Hg, and 93.3% of patients had mild or lesser total PR. The Kaplan-Meier estimate of all-cause mortality was 3.5% at 3 years. There were no cases of coronary artery compression, hemopericardium, or endocarditis. CONCLUSIONS: This analysis reports the longest follow-up in the largest cohort of patients from the ALTERRA trials. The Alterra Adaptive Prestent with the SAPIEN 3 THV system has shown excellent procedural outcomes and is effective in reducing PR at 3-year follow-up. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03130777.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (1) , e012860
Association Between a Novel Adult Congenital Heart Disease-Specific Patient-Reported Health Status Metric and Objective Clinical Status
BACKGROUND: Although disease-specific patient-reported outcomes (PROs) are well accepted as direct and indirect clinical outcomes in various diseases, data on PRO performance in adult congenital heart disease (ACHD) are limited to nondisease-specific metrics. We, therefore, investigated the association between responses to a novel ACHD-specific PRO metric and both clinical variables and gold standard PROs. METHODS: We assessed the association between patient-perceived health status as assessed by the summary score of the Adult Congenital Heart Disease Patient-Reported Outcome Version 1 (ACHD PRO V.1) and hospital admission within the preceding 5 years in the English-speaking subgroup of an international cohort of patients with ACHD enrolled in APPROACH IS-II between February 10, 2019, and December 14, 2022. We also examined the relationship between ACHD PRO V.1 domain scores and domain-relevant clinical variables, the Linear Analog Scale Quality of Life, the Patient Health Questionnaire-8, and the Generalized Anxiety Disorder-7. RESULTS: The analysis includes 333 patients. Both unadjusted and adjusted models revealed that worse patient-perceived health status was associated with unplanned hospital admission (adjusted β, −5.7 [95% CI, −9.9 to −1.6]; P =0.007). Univariate analysis indicated a strong association between ACHD PRO V.1 domains and relevant clinical variables. A moderate correlation was found between the QOL and anxiety/depression domains and their corresponding gold standard ( r =0.467, P r =−0.581, P r =−0.540, P <0.001 with the Generalized Anxiety Disorder-7). CONCLUSIONS: A lower ACHD PRO V.1 summary score is associated with a history of unplanned cardiac admission. In addition, the ACHD PRO V.1 domains show good content validity by comparison with relevant clinical conditions and gold standard PROs. These data support the use of the ACHD PRO V.1 as a direct and surrogate clinical outcome in ACHD.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (1) , e012860
Association Between a Novel Adult Congenital Heart Disease-Specific Patient-Reported Health Status Metric and Objective Clinical Status
BACKGROUND: Although disease-specific patient-reported outcomes (PROs) are well accepted as direct and indirect clinical outcomes in various diseases, data on PRO performance in adult congenital heart disease (ACHD) are limited to nondisease-specific metrics. We, therefore, investigated the association between responses to a novel ACHD-specific PRO metric and both clinical variables and gold standard PROs. METHODS: We assessed the association between patient-perceived health status as assessed by the summary score of the Adult Congenital Heart Disease Patient-Reported Outcome Version 1 (ACHD PRO V.1) and hospital admission within the preceding 5 years in the English-speaking subgroup of an international cohort of patients with ACHD enrolled in APPROACH IS-II between February 10, 2019, and December 14, 2022. We also examined the relationship between ACHD PRO V.1 domain scores and domain-relevant clinical variables, the Linear Analog Scale Quality of Life, the Patient Health Questionnaire-8, and the Generalized Anxiety Disorder-7. RESULTS: The analysis includes 333 patients. Both unadjusted and adjusted models revealed that worse patient-perceived health status was associated with unplanned hospital admission (adjusted β, −5.7 [95% CI, −9.9 to −1.6]; P =0.007). Univariate analysis indicated a strong association between ACHD PRO V.1 domains and relevant clinical variables. A moderate correlation was found between the QOL and anxiety/depression domains and their corresponding gold standard ( r =0.467, P r =−0.581, P r =−0.540, P <0.001 with the Generalized Anxiety Disorder-7). CONCLUSIONS: A lower ACHD PRO V.1 summary score is associated with a history of unplanned cardiac admission. In addition, the ACHD PRO V.1 domains show good content validity by comparison with relevant clinical conditions and gold standard PROs. These data support the use of the ACHD PRO V.1 as a direct and surrogate clinical outcome in ACHD.
- Open Access
Perceived health, psychological distress and quality of life in 8415 adults with congenital heart disease from 32 countries
Background The global prevalence of congenital heart disease (CHD) is increasing. Research on patient-reported outcomes (PROs) predominantly originates from high-income countries, resulting in an incomplete understanding of the true global burden of CHD from the patient perspective. Therefore, we described perceived health, psychological distress and quality of life (QoL) in a large sample of adults with CHD from the globe and explored the relationship between PROs and the income level of the countries. Methods Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart Disease—International Study II (APPROACH-IS II) represents an international cross-sectional investigation of PROs in 8415 patients from 53 centres across 32 countries. Patients completed questionnaires to measure perceived health status (RAND-12 Health Survey; EuroQOL-5D Visual Analog Scale); depressive symptoms (Patient Health Questionnaire-8, PHQ-8); anxiety (Generalized Anxiety Disorder Scale-7) and QoL (Linear Analog Scale). Gross National Income per capita in US dollars was used for stratifying countries according to income levels. Results Large intercountry disparities in PROs were observed. Switzerland demonstrated the highest mean scores for physical functioning, self-rated health and QoL, while Senegal had the lowest scores. Patients from Malta demonstrated the highest mean scores for mental health, and Senegal had the lowest scores. With regard to depressive symptoms and anxiety, Pakistan had the lowest mean scores, while Turkey had the highest scores. Patients from high-income nations reported significantly better physical functioning, mental functioning and QoL. Conclusion Large intercountry disparities in PROs were observed. APPROACH-IS II is a pioneering international endeavour that comprehensively evaluated PROs among adults with CHD, drawing participants from nations with different income levels. Trial registration number NCT04902768.
Open AccessPerceived health, psychological distress and quality of life in 8415 adults with congenital heart disease from 32 countries
Background The global prevalence of congenital heart disease (CHD) is increasing. Research on patient-reported outcomes (PROs) predominantly originates from high-income countries, resulting in an incomplete understanding of the true global burden of CHD from the patient perspective. Therefore, we described perceived health, psychological distress and quality of life (QoL) in a large sample of adults with CHD from the globe and explored the relationship between PROs and the income level of the countries. Methods Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart Disease—International Study II (APPROACH-IS II) represents an international cross-sectional investigation of PROs in 8415 patients from 53 centres across 32 countries. Patients completed questionnaires to measure perceived health status (RAND-12 Health Survey; EuroQOL-5D Visual Analog Scale); depressive symptoms (Patient Health Questionnaire-8, PHQ-8); anxiety (Generalized Anxiety Disorder Scale-7) and QoL (Linear Analog Scale). Gross National Income per capita in US dollars was used for stratifying countries according to income levels. Results Large intercountry disparities in PROs were observed. Switzerland demonstrated the highest mean scores for physical functioning, self-rated health and QoL, while Senegal had the lowest scores. Patients from Malta demonstrated the highest mean scores for mental health, and Senegal had the lowest scores. With regard to depressive symptoms and anxiety, Pakistan had the lowest mean scores, while Turkey had the highest scores. Patients from high-income nations reported significantly better physical functioning, mental functioning and QoL. Conclusion Large intercountry disparities in PROs were observed. APPROACH-IS II is a pioneering international endeavour that comprehensively evaluated PROs among adults with CHD, drawing participants from nations with different income levels. Trial registration number NCT04902768.
- Open Access
- 24 June 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101902
Predictors of Length-of-Stay Among Transcatheter Aortic Valve Replacement Patients Using a Supervised Machine Learning Algorithm
- 24 June 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101902
Open AccessPredictors of Length-of-Stay Among Transcatheter Aortic Valve Replacement Patients Using a Supervised Machine Learning Algorithm
- 14 October 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (19) , 2287-2297
Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation
- 14 October 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (19) , 2287-2297
Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation
- 6 June 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (1) , 93-115
Structural Heart Imaging Using 3-Dimensional Intracardiac Echocardiography
- 6 June 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (1) , 93-115
Structural Heart Imaging Using 3-Dimensional Intracardiac Echocardiography
- Open Access
- 3 May 2024
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 3 (6) , 102016
Transcatheter Closure of Postinfarct VSD With the Amplatzer PIVSD Occluder: Results of a US Study
- 3 May 2024
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 3 (6) , 102016
Open AccessTranscatheter Closure of Postinfarct VSD With the Amplatzer PIVSD Occluder: Results of a US Study